Taking forward the key TIGRR recommendations | Moving licensing from Home Office to DHSC
centreformedicinalcannabis.substack.com
Our second paper from Decalogue is written by a collective of experts working in the cannabis space.
Dr Andy Yates, Chief Scientific Officer, Artelo Biosciences
Dr Parveen Bhatarah, Regulatory and Compliance Lead, The Centre for Medicinal Cannabis
Dr Paul Dickenson, Founder, SEDA Pharmaceuticals
Steve McConchie, CEO, Aptus Clinical
Taking forward the key TIGRR recommendations | Moving licensing from Home Office to DHSC | Abstract
The UK has a strong history of pharmaceutical R&D leading to the approval of significant medicines from antibiotics to monoclonal antibodies. More recently it has been the home for the world’s first biotech focused on developing cannabinoid medicines (GW Pharma). Current interest in the benefits of cannabinoid medicines and the new regulatory freedoms afforded by Brexit should make the UK a “go-to” global hub for cannabinoid R&D and lead to first major market regulatory approval. Real-life experience has shown the difficulties of developing controlled drugs such as cannabinoids, as licensing of activities across the R&D supply chain is controlled by the Home Office and not the MHRA. We make the case that for cannabinoids being developed in regulated clinical trials the licensing authority should transition from the Home Office to the MHRA which will speed development, reduce cost and red-tape and lead to increased R&D expenditure within the UK.
Taking forward the key TIGRR recommendations | Moving licensing from Home Office to DHSC
Taking forward the key TIGRR recommendations | Moving licensing from Home Office to DHSC
Taking forward the key TIGRR recommendations | Moving licensing from Home Office to DHSC
Our second paper from Decalogue is written by a collective of experts working in the cannabis space.
Dr Andy Yates, Chief Scientific Officer, Artelo Biosciences
Dr Parveen Bhatarah, Regulatory and Compliance Lead, The Centre for Medicinal Cannabis
Dr Paul Dickenson, Founder, SEDA Pharmaceuticals
Steve McConchie, CEO, Aptus Clinical
Taking forward the key TIGRR recommendations | Moving licensing from Home Office to DHSC | Abstract
The UK has a strong history of pharmaceutical R&D leading to the approval of significant medicines from antibiotics to monoclonal antibodies. More recently it has been the home for the world’s first biotech focused on developing cannabinoid medicines (GW Pharma). Current interest in the benefits of cannabinoid medicines and the new regulatory freedoms afforded by Brexit should make the UK a “go-to” global hub for cannabinoid R&D and lead to first major market regulatory approval. Real-life experience has shown the difficulties of developing controlled drugs such as cannabinoids, as licensing of activities across the R&D supply chain is controlled by the Home Office and not the MHRA. We make the case that for cannabinoids being developed in regulated clinical trials the licensing authority should transition from the Home Office to the MHRA which will speed development, reduce cost and red-tape and lead to increased R&D expenditure within the UK.